Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

• Status: Completed
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of antipsychotic.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Greater Los Angeles Healthcare System
• Collaborators: Stanley Medical Research Institute; Theravalues, Inc.; University of California, Los Angeles
• Treatments: Curcumin

Criteria

Inclusion Criteria:

• DSM-5 diagnosis of schizophrenia

• age 18 - 65 years

• understand spoken English sufficiently to comprehend testing procedures

• corrected vision of at least 20/30

• currently prescribed an antipsychotic medication

Exclusion Criteria:

• clinically significant neurological disease determined by medical history (e.g., epilepsy)

• history of serious head injury (i.e., loss of consciousness > 1 hr., no neuropsychological sequelae, no cognitive rehabilitation post head injury)

• sedatives or benzodiazepines within 12 hrs of testing

• any psychiatric hospitalization within 3 months prior to study participation

• behaviors suggesting any potential danger to self or others within 6 months prior to study participation

• antipsychotic dose change more than 50% over the 3 months prior to study participation

• acute medical problems or untreated chronic medical conditions within 3 months prior to study participation